Keros Therapeutics Stock Meets 80-Plus RS Rating Benchmark

Keros Therapeutics Stock Meets 80-Plus RS Rating Benchmark·Investor's Business Daily

Keros Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 66 to 86.

Advertisement